Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

• Status: Completed
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine or Liposomal Bupivicaine for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas Medical Center
• Treatments: Bupivacaine; Lidocaine

Criteria

Inclusion Criteria:

• Spanish/English speaking

• <20%TBSA; <5% TBSA deep partial or full thickness burns

Exclusion Criteria:

• chronic pain syndrome

• > 20% TBSA burn injury; > 5% TBSA deep partial or full thickness burn

• pregnant

• allergy to lidocaine or other local anesthetics

• burns to anterior thighs